FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022900779> ?p ?o ?g. }

• W2022900779 endingPage "91" @default.
• W2022900779 startingPage "85" @default.
• W2022900779 abstract "Evaluar el papel del estudio multiparamétrico mediante imagen por resonancia magnética (mpMRI) de próstata para detectar cáncer de próstata en pacientes con biopsia prostática transrectal (BPTR) negativa previa. Se practicó una mpMRI (secuencias TSE-T2-w, DWI y DCE) de la próstata con equipo de 1.5 T (Magnetom Avanto; Siemens Healthcare Solutions) a 150 pacientes con sospecha previa de cáncer de próstata y BPTR negativa. Se aplicaron criterios de European Society of Urogenital Radiology (ESUR) (1: muy posiblemente benigno, 2: posiblemente benigno, 3: dudoso, 4: posiblemente maligno, y 5: muy posiblemente maligno). A todos los pacientes se les realizó PSA (total y libre), tacto rectal (TR), ecografía transrectal (ETR) y segunda BPTR de, al menos, 14 cilindros. Las variables fueron analizadas de forma ciega independiente. Se estudió la exactitud de cada prueba y se evaluó un modelo de selección de variables stepwise para predecir cáncer en la segunda BPTR. La edad media ± desviación estándar fue 66,2 ± 5 (51-77) años, el PSA 11,3 ± 9,6 (0,9-75) ng/mL y el volumen prostático 82,2 ± 42 (20-250) cc. El TR fue sospechoso en 11(7,3%) pacientes. La segunda BPTR muestreó 17,6 ± 2,7 (14-22) cilindros por caso y resultó positiva en 28 (18,7%) pacientes. La mpMRI se consideró positiva (3-5) en 102 (68%), siendo la sensibilidad de la prueba del 92,9% y el VPN del 95,8%. Modifican riesgo de cáncer en segunda BPTR: velocidad de PSA > 0,75 (OR 1,04 [0,99-1,08]); p = 0,06), PSA libre/total < 15% (OR 0,37 [0,13-1,05]; p = 0,06), cada cc de volumen prostático (OR 0,98 [0,97-1]; p = 0,017) y mpMRI 3-5 (OR 7,87 [1,78-34,7]; p = 0,006). El análisis multivariante reveló que mpMRI (OR 7,41 [1,65-33,28]; p = 0,009) y volumen prostático (OR 0,31 [0,12-0,78]; p = 0,01) definen riesgo de cáncer de forma independiente. La mpMRI según criterios ESUR es una herramienta de gran valor para predecir la presencia de cáncer en la segunda BPTR en pacientes con biopsia previa negativa y resulta más fiable en próstatas de menor volumen. To assess the ability of multiparametric prostate magnetic resonance imaging (mpMRI) to detect prostate cancer in patients with prior negative transrectal prostate biopsy (TPB). mpMRI (TSE-T2-w, DWI and DCE sequences) was performed on 1.5 T (Magnetom Avanto; Siemens Healthcare Solutions) in 150 patients suspicious of prostate cancer and with negative TPB. European Society of Urogenital Radiology (ESUR) criteria were used (score 1: clinically significant disease is highly unlikely to be present; score 2: clinically significant cancer is unlikely to be present; score 3: clinically significant cancer is equivocal; score 4: clinically significant cancer is likely to be present; score 5: clinically significant cancer is highly likely to be present). PSA measurement (total and free), digital rectal examination (DRE), transrectal ultrasound (TRU) and a second TPB (at least 14 cylinders) were performed in all patients. Variables were submitted for independent blind analysis. The accuracy of each test was measured. Stepwise selection model for prediction of prostate cancer in second TPB was developed. Mean age was 66.2± 5 years (51-77), mean PSA 11.3± 9.6 ng/mL (0.9-75) and mean prostatic volume 82.2 ± 42 (20-250) cc. DRE was suspicious in 11 (7.3%) patients. The mean number of cylinders per patient sampled in second TRB was 17.6 ± 2.7(14-22). Second TRB was positive in 28 patients (18.7%). mpMRI was positive (score 3-5) in 102 (68%), test sensibility was 92.9% and the NPV was 95.8%. The risk of prostate cancer diagnosis in second TPB is modified by: PSA velocity > 0.75 (OR 1.04 [0.99-1.08]; P=0.06), free/total ratio PSA <15% (OR 0.37 [0.13-1.05]; P=0.06), each cc. of prostate volume (OR 0.98 [0.97-1]; P=0.017) and mpMRI 3-5 (OR 7.87 [1.78-34.7]; P=0.006). Multivariate analysis reveals that mpMRI (OR 7.41 [1.65-33.28]; P=0.009) and prostatic volume (OR 0.31 [0.12-0.78]; P=0.01) are independent risk predictors of prostate cancer. According to ESUR guidelines and in patients with prior negative prostate biopsy, mpMRI is a valuable tool for the prediction of prostate cancer in second TPB. Lower prostate volume, the higher reliability" @default.
• W2022900779 created "2016-06-24" @default.
• W2022900779 creator A5011270213 @default.
• W2022900779 creator A5017900696 @default.
• W2022900779 creator A5032410683 @default.
• W2022900779 creator A5035212985 @default.
• W2022900779 creator A5069928469 @default.
• W2022900779 creator A5089439116 @default.
• W2022900779 date "2015-03-01" @default.
• W2022900779 modified "2023-09-28" @default.
• W2022900779 title "La resonancia magnética multiparamétrica predice la presencia de cáncer de próstata en pacientes con biopsia prostática negativa" @default.
• W2022900779 cites W1483897994 @default.
• W2022900779 cites W1529297144 @default.
• W2022900779 cites W1584354058 @default.
• W2022900779 cites W2003769757 @default.
• W2022900779 cites W2010902574 @default.
• W2022900779 cites W2012650059 @default.
• W2022900779 cites W2013957566 @default.
• W2022900779 cites W2027142966 @default.
• W2022900779 cites W2028823180 @default.
• W2022900779 cites W2061259677 @default.
• W2022900779 cites W2064734791 @default.
• W2022900779 cites W2068628031 @default.
• W2022900779 cites W2084834212 @default.
• W2022900779 cites W2091609181 @default.
• W2022900779 cites W2115736013 @default.
• W2022900779 cites W2115895082 @default.
• W2022900779 cites W2119391023 @default.
• W2022900779 cites W2124539070 @default.
• W2022900779 cites W2147793891 @default.
• W2022900779 cites W2148844122 @default.
• W2022900779 cites W2169285591 @default.
• W2022900779 cites W2323868208 @default.
• W2022900779 doi "https://doi.org/10.1016/j.acuro.2014.07.001" @default.
• W2022900779 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25267460" @default.
• W2022900779 hasPublicationYear "2015" @default.
• W2022900779 type Work @default.
• W2022900779 sameAs 2022900779 @default.
• W2022900779 citedByCount "8" @default.
• W2022900779 countsByYear W20229007792016 @default.
• W2022900779 countsByYear W20229007792017 @default.
• W2022900779 countsByYear W20229007792019 @default.
• W2022900779 countsByYear W20229007792021 @default.
• W2022900779 crossrefType "journal-article" @default.
• W2022900779 hasAuthorship W2022900779A5011270213 @default.
• W2022900779 hasAuthorship W2022900779A5017900696 @default.
• W2022900779 hasAuthorship W2022900779A5032410683 @default.
• W2022900779 hasAuthorship W2022900779A5035212985 @default.
• W2022900779 hasAuthorship W2022900779A5069928469 @default.
• W2022900779 hasAuthorship W2022900779A5089439116 @default.
• W2022900779 hasConcept C29456083 @default.
• W2022900779 hasConcept C2989005 @default.
• W2022900779 hasConcept C71924100 @default.
• W2022900779 hasConceptScore W2022900779C29456083 @default.
• W2022900779 hasConceptScore W2022900779C2989005 @default.
• W2022900779 hasConceptScore W2022900779C71924100 @default.
• W2022900779 hasIssue "2" @default.
• W2022900779 hasLocation W20229007791 @default.
• W2022900779 hasLocation W20229007792 @default.
• W2022900779 hasOpenAccess W2022900779 @default.
• W2022900779 hasPrimaryLocation W20229007791 @default.
• W2022900779 hasRelatedWork W1506200166 @default.
• W2022900779 hasRelatedWork W1995515455 @default.
• W2022900779 hasRelatedWork W2048182022 @default.
• W2022900779 hasRelatedWork W2080531066 @default.
• W2022900779 hasRelatedWork W2604872355 @default.
• W2022900779 hasRelatedWork W2748952813 @default.
• W2022900779 hasRelatedWork W2899084033 @default.
• W2022900779 hasRelatedWork W3031052312 @default.
• W2022900779 hasRelatedWork W3032375762 @default.
• W2022900779 hasRelatedWork W3108674512 @default.
• W2022900779 hasVolume "39" @default.
• W2022900779 isParatext "false" @default.
• W2022900779 isRetracted "false" @default.
• W2022900779 magId "2022900779" @default.
• W2022900779 workType "article" @default.